166 related articles for article (PubMed ID: 12669387)
1. Balofloxacin Choongwae.
Alksne L
Curr Opin Investig Drugs; 2003 Feb; 4(2):224-9. PubMed ID: 12669387
[TBL] [Abstract][Full Text] [Related]
2. Pazufloxacin Toyama Chemical Co.
Johnson AP
Curr Opin Investig Drugs; 2000 Sep; 1(1):52-7. PubMed ID: 11249595
[TBL] [Abstract][Full Text] [Related]
3. Moxifloxacin Bayer.
Barrett JF
Curr Opin Investig Drugs; 2000 Sep; 1(1):45-51. PubMed ID: 11249594
[TBL] [Abstract][Full Text] [Related]
4. Gatifloxacin Kyorin Pharmaceutical Co.
Brown WM
Curr Opin Investig Drugs; 2000 Sep; 1(1):35-44. PubMed ID: 11249593
[TBL] [Abstract][Full Text] [Related]
5. Fluoroquinolones.
Molavi A
Am Fam Physician; 1988 May; 37(5):279-84. PubMed ID: 3284309
[No Abstract] [Full Text] [Related]
6. Prescribing considerations in fluoroquinolone therapy.
Gentry LO
Pharmacotherapy; 1993; 13(2 Pt 2):39S-44S. PubMed ID: 8474937
[TBL] [Abstract][Full Text] [Related]
7. MBI-226. Micrologix/Fujisawa.
Isaacson RE
Curr Opin Investig Drugs; 2003 Aug; 4(8):999-1003. PubMed ID: 14508884
[TBL] [Abstract][Full Text] [Related]
8. Laboratory and clinical study of balofloxacin (Q-35), a new fluoroquinolone, in urinary tract infection.
Suzuki K; Horiba M; Ishikawa K; Katoh S; Naide Y; Yanaoka M; Andoh S
Drugs; 1995; 49 Suppl 2():376-8. PubMed ID: 8549367
[No Abstract] [Full Text] [Related]
9. Olamufloxacin. Hokuriku Seiyaku.
Jiraskova N
Curr Opin Investig Drugs; 2000 Sep; 1(1):31-4. PubMed ID: 11249592
[TBL] [Abstract][Full Text] [Related]
10. Current challenges in the treatment of complicated urinary tract infections and prostatitis.
Wagenlehner FM; Naber KG
Clin Microbiol Infect; 2006 May; 12 Suppl 3():67-80. PubMed ID: 16669930
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of new anti-infective drugs for the treatment of urinary tract infection. Infectious Diseases Society of America and the Food and Drug Administration.
Rubin RH; Shapiro ED; Andriole VT; Davis RJ; Stamm WE
Clin Infect Dis; 1992 Nov; 15 Suppl 1():S216-27. PubMed ID: 1477233
[TBL] [Abstract][Full Text] [Related]
12. [Supplementary enzyme treatment of urinary tract infections].
Naber K
Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 9():S327-30. PubMed ID: 19085664
[No Abstract] [Full Text] [Related]
13. [Fluoroquinolone. 2. Pharmacokinetics and clinical use].
Kemmerich B; Stahlmann R; Lode H
Dtsch Med Wochenschr; 1988 Apr; 113(17):693-5. PubMed ID: 3282865
[No Abstract] [Full Text] [Related]
14. Iclaprim, a diaminopyrimidine dihydrofolate reductase inhibitor for the potential treatment of antibiotic-resistant staphylococcal infections.
Peppard WJ; Schuenke CD
Curr Opin Investig Drugs; 2008 Feb; 9(2):210-25. PubMed ID: 18246524
[TBL] [Abstract][Full Text] [Related]
15. Ceftaroline fosamil, a cephalosporin derivative for the potential treatment of MRSA infection.
Parish D; Scheinfeld N
Curr Opin Investig Drugs; 2008 Feb; 9(2):201-9. PubMed ID: 18246523
[TBL] [Abstract][Full Text] [Related]
16. Telavancin (Theravance).
Pace JL; Judice JK
Curr Opin Investig Drugs; 2005 Feb; 6(2):216-25. PubMed ID: 15751746
[TBL] [Abstract][Full Text] [Related]
17. Acute, uncomplicated, lower urinary tract infections: the role of single-dose fleroxacin.
Kosmidis J; Gargalianos P; Lelekis M; Adamis G; Petropoulou D; Makris D
J Chemother; 1989 Jul; 1(4 Suppl):864-5. PubMed ID: 16312675
[No Abstract] [Full Text] [Related]
18. Choosing the ideal antibiotic therapy and the role of the newer fluoroquinolones in respiratory tract infections.
Owens RC
Am J Manag Care; 2000 May; 6(8 Suppl):S442-7. PubMed ID: 10977484
[No Abstract] [Full Text] [Related]
19. Nicaraven Chugai.
Leker RR
Curr Opin Investig Drugs; 2003 Jan; 4(1):83-90. PubMed ID: 12625035
[TBL] [Abstract][Full Text] [Related]
20. [New fluoroquinolones in urology].
Derevianko II; Hefedova LA
Urologiia; 2004; (4):27-32. PubMed ID: 15457949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
